EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Crescita Therapeutics Inc (CRRTF) fair value: what the stock is really worth

As of Jun 4, 2026: fair value of Crescita Therapeutics Inc $0.85, price $0.56, upside +52.1%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN CA2258471028

CT Crescita Therapeutics Inc logo Thin data Sep 24, 2026

Crescita Therapeutics Inc

CRRTF · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $0.8500 · Strongly undervalued (+52.1%)
✓Quality 68/100
!Weak Growth (revenue 5y +6.2 %/yr)
!Loss-making · -1.4% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 14/100
!Evidence only low, so the estimate is less certain
Watch Crescita Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.39 $0.0210 Fair Value $0.8500 Apr 2016 Jun 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0210 – $1.39 · fair‑value band $0.5900 – $1.22 · the $0.5587 price screens below the $0.8500 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services.

Show more

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes Bacti Control, a solution for hand hygiene; NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. As of June 3, 2026, Crescita Therapeutics Inc. operates as a subsidiary of ClinActiv Holdings Inc.

Stock analysis

Crescita Therapeutics Inc (CRRTF) currently trades at $0.5587, while our model-based Fair Value estimate is $0.8500, implying the stock looks roughly 34.3% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.8500 per share, and 9 of the 11 models we run sit above the $0.5587 price.

Bear case: the Asset-Based group reads lowest at $0.3900, and 2 of the 11 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.5900 (bear) to $1.22 (bull), the price of $0.5587 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Crescita Therapeutics Inc reported revenue of C$21.1M in FY2025 versus C$16.8M in FY2021, a compound +5.9%/yr. Reported net income was −C$91.9K in FY2025.

Key figures

Market cap $10.5M · P/S ratio 0.45 · EPS (TTM) $−0.0100 · Dividend yield 0.1% · Net margin −0.4% · Return on equity −2.2% · Return on assets (EBIT) −5.7% · Operating margin −21.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 3% below its 52-week high and 136% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 52%, CRRTF screens cheaper than that median.

Fair Value models

Bear $0.5900 Fair Value $0.8500 Bull $1.22
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.6900 $1.00 $1.78 78
Growth DCF $0.6800 $1.07 $1.68 77
5Y EBITDA Exit $0.5400 $0.7300 $0.9700 76
All 11 models by family
DCF Models
FCF DCF $0.6900 $1.00 $1.78 78
Owner Earnings $0.8700 $1.48 $2.63 74
5Y Revenue Exit $0.5900 $0.8500 $1.22 73
5Y EBITDA Exit $0.5400 $0.7300 $0.9700 76
10Y Revenue Exit $0.6100 $0.8800 $1.30 66
10Y EBITDA Exit $0.5900 $0.7900 $1.11 69
Multiples
EV/EBITDA $0.4800 $0.5400 $0.6000 67
EV/Revenue $0.5400 $0.6500 $0.7600 54
Asset-Based
NCAV (Graham) $0.2900 $0.3900 $0.5900 53
Growth DCF
Growth DCF $0.6800 $1.07 $1.68 77
Rev-Margin DCF $0.5900 $0.8400 $1.19 73

Open the full fair value analysis →

Notify me when CRRTF reaches fair value

Put CRRTF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 68/100

Of which business quality 67 · Market factors (momentum, volatility) 67

Profitability 42
Margins and returns on capital today
Quality Growth 79
Are margins and returns improving?
Cashflow 38
Earnings quality: real cash, not paper profit
Fin. Strength 74
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 79
Price trend over the last 3–12 months (market factor)
52W Momentum 65
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic). Over 10 years: +37.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.9% (2020) → −4.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CAD, Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −2.9% a year for the price.

Watch CRRTF, get fair value alerts →

Compare Crescita Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside +25.3% · Top 25%
Profitability
Return on assets −3.3% · Bottom 25%
Net margin (TTM) −1.4% · Below median
Operating margin (TTM) −21.4% · Bottom 25%
Growth and dividend
Revenue growth 59.4% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.67× · Cheapest 25%
P/S (TTM) 0.45× · Cheapest 25%
P/FCF 14.1× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Crescita Therapeutics Inc · Fair Value
$0.8500 +34%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Crescita Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/CRRTF

Frequently asked questions

Is Crescita Therapeutics Inc (CRRTF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.8500 versus the last price from Jun 4, 2026 of $0.5587, about +52% upside (undervalued).
What is the fair value of CRRTF?
Our model-based fair value for Crescita Therapeutics Inc is $0.8500 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jun 4, 2026): $0.5587.
What is the quality score of CRRTF?
Crescita Therapeutics Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Crescita Therapeutics Inc (CRRTF)?
Our model-based price target is the fair value of $0.8500 (as of Sep 24, 2026) from 11 valuation models. Cautious scenario $0.5900, optimistic scenario $1.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Crescita Therapeutics Inc stock forecast for 2026?
Our models put fair value at $0.8500, about +52% upside versus the last price from Jun 4, 2026 of $0.5587 (undervalued). Cautious scenario $0.5900, optimistic scenario $1.22. The calculation is refreshed regularly with new filings.
What is the revenue of Crescita Therapeutics Inc (CRRTF)?
Crescita Therapeutics Inc reported trailing-twelve-month revenue of about C$23.2M (latest available figure, as of Sep 24, 2026).
Does Crescita Therapeutics Inc pay a dividend?
Crescita Therapeutics Inc currently shows a dividend yield of about 0.06% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Crescita Therapeutics Inc (CRRTF)?
For today's price to be fair in a discounted-cash-flow model, Crescita Therapeutics Inc would have to grow free cash flow by -0.8 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CRRTF use?
Our models discount Crescita Therapeutics Inc at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Crescita Therapeutics Inc that is -0.8 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Crescita Therapeutics Inc (CRRTF) delivered so far?
Over the past 5 years revenue at Crescita Therapeutics Inc grew +6.2 % a year. The price currently implies -0.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Crescita Therapeutics Inc (CRRTF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Crescita Therapeutics Inc (-0.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Crescita Therapeutics Inc (CRRTF)?
The free-cash-flow yield on the price is 4.93 %: that much free cash flow Crescita Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Crescita Therapeutics Inc (CRRTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Crescita Therapeutics Inc it is $0.8500 per share (as of Sep 24, 2026), against a price of $0.5587. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Crescita Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CRRTF trades below its calculated fair value: price $0.5587, fair value $0.8500, a gap of about +52% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRRTF?
No. The price is what the market pays today ($0.5587); the fair value is what the company's own numbers justify ($0.8500). For Crescita Therapeutics Inc the two are $0.2913 per share apart. That gap is exactly why we show both numbers side by side.
How much is Crescita Therapeutics Inc worth?
The market values Crescita Therapeutics Inc at about $10.5M (market capitalisation, as of Sep 24, 2026). Per share that is $0.5587; our models calculate a fair value of $0.8500 per share.
What do the bullish and bearish scenarios say about CRRTF?
Our models span a range for Crescita Therapeutics Inc: cautious scenario $0.5900, base $0.8500, optimistic $1.22 per share (as of Sep 24, 2026, price $0.5587). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Crescita Therapeutics Inc (CRRTF)?
Balance-sheet figures for Crescita Therapeutics Inc (as of Sep 24, 2026): return on equity −2.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is CRRTF from its 52-week high?
Crescita Therapeutics Inc trades at $0.5587, about 3% below its 52-week high of $0.5731 and 136% above the low of $0.2371 (as of Jun 4, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8500 is for.
Which stocks are comparable to Crescita Therapeutics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Crescita Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $0.5587, calculated fair value $0.8500 (+52%), Quality Score 68/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRRTF calculated?
We run Crescita Therapeutics Inc through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.8500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Crescita Therapeutics Inc currently trades 34 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Crescita Therapeutics Inc (CRRTF)?
The latest price we hold is from Jun 4, 2026 and stands at $0.5587. Our model-based fair value is $0.8500, about +52% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Crescita Therapeutics Inc right now?
The price is below even our cautious bear case ($0.5900). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.5900 to $1.22) leaves room in how you read the outcome.

Key figures of Crescita Therapeutics Inc

How large is the market capitalisation of Crescita Therapeutics Inc (CRRTF)?
The market capitalisation of Crescita Therapeutics Inc is $10.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Crescita Therapeutics Inc (CRRTF)?
The price-to-sales ratio of Crescita Therapeutics Inc is 0.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Crescita Therapeutics Inc (CRRTF)?
Earnings per share at Crescita Therapeutics Inc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Crescita Therapeutics Inc (CRRTF)?
The dividend yield of Crescita Therapeutics Inc is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Crescita Therapeutics Inc (CRRTF)?
The net margin of Crescita Therapeutics Inc is −0.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Crescita Therapeutics Inc (CRRTF)?
The return on equity (ROE) of Crescita Therapeutics Inc is −2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Crescita Therapeutics Inc (CRRTF)?
On an EBIT basis the return on assets of Crescita Therapeutics Inc is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Crescita Therapeutics Inc (CRRTF)?
The operating margin of Crescita Therapeutics Inc is −21.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Crescita Therapeutics Inc (CRRTF)?
Revenue at Crescita Therapeutics Inc is growing +59.4% versus a year earlier (3y avg −3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Crescita Therapeutics Inc (CRRTF)?
Earnings per share at Crescita Therapeutics Inc are growing +28.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Crescita Therapeutics Inc (CRRTF) hold?
Crescita Therapeutics Inc holds more cash than debt, C$8.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Crescita Therapeutics Inc in the live analysis

One click puts Crescita Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.